Skip to main content
GlaxoSmithkline Pharmaceuticals Ltd. logo

GlaxoSmithkline Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · GLAXO ISIN · INE159A01016 LEI · 3358002TNSC1U2DWNY52 BSE.NS Manufacturing
Open in API
Filings indexed 1,605 across all filing types
Latest filing 2026-02-03 Regulatory Filings
Country IN India
Listing BSE.NS GLAXO

About GlaxoSmithkline Pharmaceuticals Ltd.

https://india-pharma.gsk.com/en-in/home/

GlaxoSmithkline Pharmaceuticals Ltd. is a research-based organization specializing in the development, manufacture, and commercialization of prescription medicines and vaccines. The company’s portfolio spans multiple therapeutic areas, including anti-infectives, dermatology, gynecology, oncology, and respiratory health. Key products include Augmentin, Calpol, Ceftum, and Eltroxin. It maintains a significant presence in the vaccines sector, offering protection against diseases such as pneumococcal infection, hepatitis, and varicella. By integrating global research and development expertise, the entity focuses on delivering innovative treatments and improving patient outcomes. Its operations are supported by a robust supply chain and distribution infrastructure designed to provide broad access to essential medical products.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice from GlaxoSmithKline Pharmaceuticals Limited addressed to stock exchanges, informing them about the schedule of an analyst/institutional investor meeting. It references compliance with SEBI Listing Regulations and provides details of the meeting date, type, and place. There is no financial data, report content, or detailed presentation included. The document is primarily an announcement of an upcoming investor meeting, not the meeting materials or transcript itself. Given the short length (1650 characters) and the nature of the content, this fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than an Investor Presentation (IP) or Call Transcript (CT).
2026-02-03 English
As per attachment
Regulatory Filings Classification · 90% confidence The document is a letter addressed to stock exchanges (BSE and NSE) informing them about the schedule of an analyst/institutional investor meeting. It references compliance with SEBI Listing Regulations and provides details of the meeting date, type, and place. The document is short (1650 characters) and does not contain any financial data, results, or detailed presentations. It is an announcement of an upcoming investor meeting rather than the meeting materials or a report. Therefore, it fits the category of an Investor Presentation announcement or update. However, since it only announces the schedule of the meeting and does not provide the presentation itself, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about investor meetings under listing obligations.
2026-02-03 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st December 2025. It is a compliance certificate from the Registrar and Share Transfer Agent confirming dematerialisation of securities and related actions. The document is addressed to stock exchanges and is a formal attestation rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or other report content. It is primarily a regulatory compliance certificate, which fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and not a financial report or announcement of a report.
2026-01-08 English
As per Attachment
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st December 2025. It is a compliance certificate from the Registrar and Share Transfer Agent confirming dematerialisation of securities and related actions. The document is short (2738 characters) and primarily serves as a regulatory compliance attestation rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. It is not an announcement of a report but a certificate fulfilling a regulatory requirement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance certificates and regulatory attestations.
2026-01-08 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-01-06 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about an upcoming Board Meeting scheduled for 9th February 2026. The purpose of the meeting is to consider and approve the unaudited financial results for the third quarter and nine months ended 31st December 2025. The document does not contain any financial data or results itself, but merely announces the meeting where such results will be discussed and approved. It is a regulatory announcement pursuant to listing obligations, not the financial report or results themselves. The document length is only 1345 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not contain substantive financial data or detailed reports.
2026-01-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.